Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hoth Therapeutics Inc HOTH

Healthcare
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s... see more

Recent & Breaking News (NDAQ:HOTH)

Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients

PR Newswire April 6, 2021

Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm

PR Newswire April 5, 2021

Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19

GlobeNewswire March 24, 2021

Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19 Therapeutic

PR Newswire March 23, 2021

Hoth Therapeutics to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021

PR Newswire March 22, 2021

Hoth Therapeutics CEO, Robb Knie, Featured on the RedChip Money Report on Bloomberg TV this Saturday, March 20th

PR Newswire March 19, 2021

Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006

PR Newswire March 17, 2021

Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease

PR Newswire March 11, 2021

Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

PR Newswire March 10, 2021

Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules

PR Newswire March 8, 2021

Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies

PR Newswire March 3, 2021

Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

PR Newswire March 1, 2021

Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment

PR Newswire February 26, 2021

Hoth Therapeutics Retains RedChip to Increase Investor Awareness

PR Newswire February 25, 2021

Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment

PR Newswire February 24, 2021

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients

PR Newswire February 23, 2021

Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)

PR Newswire February 18, 2021

Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth Invitational 2021 Virtual Conference

PR Newswire February 17, 2021

Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv

PR Newswire February 10, 2021

Voltron Therapeutics, Inc. Initiates Additional Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19

GlobeNewswire February 9, 2021